Evidence method
Level · gp.fundamentals.capex_revenue_ratio
132.30% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Mar 31, 2019
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001564590-19-015366General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-566.20% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
96.12% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
89.95% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-567.03% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
387.84% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
96.21% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History17 statesSelf-history eligible
Sep 30, 20180/7 normalizedLevel 3Dec 31, 20180/7 normalizedLevel 3Mar 31, 20190/7 normalizedLevel 3Jun 30, 20190/8 normalizedLevel 3Sep 30, 20190/8 normalizedLevel 3Dec 31, 20190/8 normalizedLevel 3Mar 31, 20200/8 normalizedLevel 3Jun 30, 20204/8 normalizedLevel 3Sep 30, 20207/8 normalizedLevel 3Dec 31, 20207/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Sep 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 169.39%
- Current
- 132.30%
- Delta
- -37.09%
- Previous
- -751.08%
- Current
- -566.20%
- Delta
- 184.88%
- Previous
- 32.13%
- Current
- 96.12%
- Delta
- 63.99%
- Previous
- 97.59%
- Current
- 89.95%
- Delta
- -7.65%
- Previous
- -1087.56%
- Current
- -567.03%
- Delta
- 520.53%
- Previous
- 674.72%
- Current
- 387.84%
- Delta
- -286.88%
- Previous
- 210.59%
- Current
- 96.21%
- Delta
- -114.38%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY INVENTORY_PRESSURE_INCREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.